Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male \& female subjects aged 13-17 years, inclusive at time of consent and at baseline visit, with a primary diagnosis of schizophrenia as defined by DSM-5 criteria and confirmed by K-SADS-PL and a history of the illness for at least 6 months prior to screening.~* PANSS score \>= 80, inclusive, at screening and baseline~Exclusion Criteria:~* Subjects with a DSM-5 diagnosis other than schizophrenia that has been the primary focus of treatment within 3 months of screening.~* Subjects with a clinical presentation or history that is consistent with delirium, dementia, amnesia or other cognitive disorders~* Subjects who have been hospitalized \> 21 days for a current exacerbation of schizophrenia at the time of baseline.~* Any neurological disorder other than Tourette's Syndrome~* Subjects at significant risk of committing violent acts, serious self-harm or suicide based on history~* Subjects with epilepsy, a history of seizures, severe head trauma or stroke~* Subjects who test positive for drugs of abuse at screening

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole (Type: EXPERIMENTAL): Participants were administered with brexpiprazole oral tablets, daily, dose titrated up to 0.5 mg by Day 4, 1 mg by Day 7, 2 mg by Day 14, then between 2-4 mg after Day 21 up to Week 6 with a 1 mg increase or decrease, based on the Investigator's decision.
- Aripiprazole (Type: ACTIVE_COMPARATOR): Participants were administered with aripiprazole oral tablets, daily, dose titrated up to 2 mg by Day 4, 5 mg by Day 7, 10 mg by Day 14, then 10, 15 or 20 mg after Day 21 up to Week 6 with a 5 mg increase or decrease, based on the Investigator's decision.
- Placebo (Type: PLACEBO_COMPARATOR): Participants were administered with brexpiprazole or aripiprazole matching placebo oral tablets, daily up to Week 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).